Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy

Diana Ovejero, Diala El-Maouche, Beth A. Brillante, Azar Khosravi, Rachel I. Gafni, Michael T. Collins

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)2D3, and tubular reabsorption of phosphate (TRP) were measured at frequent time points during treatment. Octreotide's effects were assessed by comparing group means of the biochemical parameters at each time-point to mean baseline values. There were no significant changes in blood phosphate, FGF23, 1,25(OH)2D3, or TRP during octreotide treatment, consistent with a lack of efficacy of octreotide in treating TIO.

Original languageEnglish (US)
Pages (from-to)1667-1671
Number of pages5
JournalJournal of Bone and Mineral Research
Volume32
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Octreotide
Phosphates
Fibroblast Growth Factor 1
Somatostatin
Therapeutics
Hypophosphatemia
Paraneoplastic Syndromes
Osteomalacia
Somatostatin Receptors
Vitamin D
Minerals
Oncogenic osteomalacia
Neoplasms
Homeostasis
Kidney
fibroblast growth factor 23

Keywords

  • CANCER
  • CELL/TISSUE SIGNALING
  • DISEASES AND DISORDERS OF/RELATED TO BONE
  • ENDOCRINE PATHWAYS
  • OSTEOMALACIA AND RICKETS
  • PTH/VIT D/FGF23
  • TUMOR-INDUCED BONE DISEASE

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Ovejero, D., El-Maouche, D., Brillante, B. A., Khosravi, A., Gafni, R. I., & Collins, M. T. (2017). Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy. Journal of Bone and Mineral Research, 32(8), 1667-1671. https://doi.org/10.1002/jbmr.3162

Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia : Results of a Short-Term Therapy. / Ovejero, Diana; El-Maouche, Diala; Brillante, Beth A.; Khosravi, Azar; Gafni, Rachel I.; Collins, Michael T.

In: Journal of Bone and Mineral Research, Vol. 32, No. 8, 01.08.2017, p. 1667-1671.

Research output: Contribution to journalArticle

Ovejero, D, El-Maouche, D, Brillante, BA, Khosravi, A, Gafni, RI & Collins, MT 2017, 'Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy', Journal of Bone and Mineral Research, vol. 32, no. 8, pp. 1667-1671. https://doi.org/10.1002/jbmr.3162
Ovejero, Diana ; El-Maouche, Diala ; Brillante, Beth A. ; Khosravi, Azar ; Gafni, Rachel I. ; Collins, Michael T. / Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia : Results of a Short-Term Therapy. In: Journal of Bone and Mineral Research. 2017 ; Vol. 32, No. 8. pp. 1667-1671.
@article{f87b34a881184a41a5d5240439556531,
title = "Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy",
abstract = "Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)2D3, and tubular reabsorption of phosphate (TRP) were measured at frequent time points during treatment. Octreotide's effects were assessed by comparing group means of the biochemical parameters at each time-point to mean baseline values. There were no significant changes in blood phosphate, FGF23, 1,25(OH)2D3, or TRP during octreotide treatment, consistent with a lack of efficacy of octreotide in treating TIO.",
keywords = "CANCER, CELL/TISSUE SIGNALING, DISEASES AND DISORDERS OF/RELATED TO BONE, ENDOCRINE PATHWAYS, OSTEOMALACIA AND RICKETS, PTH/VIT D/FGF23, TUMOR-INDUCED BONE DISEASE",
author = "Diana Ovejero and Diala El-Maouche and Brillante, {Beth A.} and Azar Khosravi and Gafni, {Rachel I.} and Collins, {Michael T.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/jbmr.3162",
language = "English (US)",
volume = "32",
pages = "1667--1671",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia

T2 - Results of a Short-Term Therapy

AU - Ovejero, Diana

AU - El-Maouche, Diala

AU - Brillante, Beth A.

AU - Khosravi, Azar

AU - Gafni, Rachel I.

AU - Collins, Michael T.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)2D3, and tubular reabsorption of phosphate (TRP) were measured at frequent time points during treatment. Octreotide's effects were assessed by comparing group means of the biochemical parameters at each time-point to mean baseline values. There were no significant changes in blood phosphate, FGF23, 1,25(OH)2D3, or TRP during octreotide treatment, consistent with a lack of efficacy of octreotide in treating TIO.

AB - Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)2D3, and tubular reabsorption of phosphate (TRP) were measured at frequent time points during treatment. Octreotide's effects were assessed by comparing group means of the biochemical parameters at each time-point to mean baseline values. There were no significant changes in blood phosphate, FGF23, 1,25(OH)2D3, or TRP during octreotide treatment, consistent with a lack of efficacy of octreotide in treating TIO.

KW - CANCER

KW - CELL/TISSUE SIGNALING

KW - DISEASES AND DISORDERS OF/RELATED TO BONE

KW - ENDOCRINE PATHWAYS

KW - OSTEOMALACIA AND RICKETS

KW - PTH/VIT D/FGF23

KW - TUMOR-INDUCED BONE DISEASE

UR - http://www.scopus.com/inward/record.url?scp=85026912590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026912590&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3162

DO - 10.1002/jbmr.3162

M3 - Article

C2 - 28459498

AN - SCOPUS:85026912590

VL - 32

SP - 1667

EP - 1671

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 8

ER -